Cybin Inc. To Officially Change Name To Helus Pharma Inc. Effective October 1, 2026
Helus Pharma (NASDAQ:HELP) (Cboe CA: HELP) ("Helus" or the "Company"), a clinical-stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists ("NSAs"), is pleased to announce the voting results for each of the matters presented at the Company’s annual and special meeting of shareholders held on September 22, 2026 (the "Meeting"). There were 107 shareholders represented in person or by proxy at the Meeting holding 46,452,598 common shares, representing 63.58% of Helus’s total issued and outstanding common shares as at the record date for the Meeting. The voting results for each matter presented at the Meeting are set out below.
The Company is also pleased to announce that, effective October 1, 2026, the Company’s legal name will be changed from "Cybin Inc." to "Helus Pharma Inc.". The legal name change follows the Company’s adoption of the business name "Helus Pharma" on January 5, 2026 and reflects the Company’s anticipated transformation from a clinical stage discovery and development company to a commercial-ready pharmaceutical company.
1. Appointment of Auditor
Zeifmans LLP was appointed auditor of Helus until the next annual meeting of shareholders at renumeration to be fixed by the directors of Helus. Voting results are set out below:
| Votes For | Votes Withheld | ||
| # | % | # | % |
| 46,084,004 | 99.207 | 368,593 | 0.793 |
2. Number of Directors
The special resolution to set the number of directors of Helus at eight was approved by at least two-thirds of the votes cast by the shareholders who voted in respect of the resolution present or represented by proxy at the Meeting. Voting results are set out below:
| Votes For | Votes Against | ||
| # | % | # | % |
| 46,139,333 | 99.326 | 313,263 | 0.674 |
3. Name Change
The special resolution to change the name of the Company from "Cybin Inc." to "Helus Pharma Inc." or such other name as may be approved by the directors, was approved by at least two-thirds of the votes cast by the shareholders who voted in respect of the resolution present or represented by proxy at the Meeting. Voting results are set out below:
| Votes For | Votes Against | ||
| # | % | # | % |
| 46,134,602 | 99.315 | 317,994 | 0.685 |
4. Election of Directors
Each of the nominees for election as director listed in Helus’s management information circular dated August 18, 2026 were elected as directors of Helus for the ensuing year or until their successors are elected or appointed. Voting results are set out below:
| Votes For | Votes Withheld | |||
| # | % | # | % | |
| Theresa Firestone | 31,992,429 | 99.239 | 245,371 | 0.761 |
| Grant Froese | 32,147,160 | 99.719 | 90,640 | 0.281 |
| Paul Glavine | 23,072,248 | 71.569 | 9,165,552 | 28.431 |
| Michael Halstead | 23,089,890 | 71.624 | 9,147,910 | 28.376 |
| Eric Hoskins | 30,895,235 | 95.835 | 1,342,565 | 4.165 |
| Mark Lawson | 32,156,082 | 99.747 | 81,718 | 0.253 |
| Freda Lewis-Hall | 23,063,327 | 71.541 | 9,174,473 | 28.459 |
| Eric So | 22,795,634 | 71.321 | 9,166,471 | 28.679 |